Is Stryker Corporation (SYK) a risky stock?
As of July 21, 2026, Clavix grades Stryker Corporation (SYK) B for risk, a composite score of 73 out of 100 on an A+ to F scale, which puts SYK in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind SYK's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how SYK scores on each, as of July 21, 2026.
What's moving SYK's risk right now
Company-specific signals Clavix flags behind SYK's current grade, drawn from recent news and filings as of July 21, 2026.
A few small investment firms grew or started positions in Stryker during the first quarter, including a 226.7% boost from Nwam LLC and a new $2.56 million stake from Blackhawk Capital. These are minor moves from small funds and unlikely to sway the stock on their own.
Stryker rolled out the Mako RPS, adding a handheld robotic option to its knee surgery product line. The launch gives surgeons more choices within the Mako platform and could pull in extra revenue.
Call options trading on Stryker has been unusually busy, suggesting some traders are betting the stock will climb soon. It points to short-term bullish bets but isn't a guarantee the price will move.
What a B grade means
On the Clavix A+ to F scale, SYK's composite of 73 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell SYK or any security. Grades are risk indicators, not predictions of return. Data may be delayed.